AR118842A2 - Composición farmacéutica que contiene tamoxifen y endoxifen y procedimiento para prepararla - Google Patents
Composición farmacéutica que contiene tamoxifen y endoxifen y procedimiento para prepararlaInfo
- Publication number
- AR118842A2 AR118842A2 ARP200101246A ARP200101246A AR118842A2 AR 118842 A2 AR118842 A2 AR 118842A2 AR P200101246 A ARP200101246 A AR P200101246A AR P200101246 A ARP200101246 A AR P200101246A AR 118842 A2 AR118842 A2 AR 118842A2
- Authority
- AR
- Argentina
- Prior art keywords
- endoxifen
- pharmaceutical composition
- composition containing
- prepare
- procedure
- Prior art date
Links
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 title abstract 6
- MHJBZVSGOZTKRH-IZHYLOQSSA-N 4-Hydroxy-N-desmethyltamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=C(O)C=C1 MHJBZVSGOZTKRH-IZHYLOQSSA-N 0.000 title abstract 3
- 229960001603 tamoxifen Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 abstract 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 229940000425 combination drug Drugs 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente se refiere a una composición farmacéutica de combinación en dosis fijas que contiene una sustancia original, cuya acción depende de la cantidad o de la actividad de las variantes de proteína expresadas, las variantes enzimáticas, las variantes del receptor o las variantes del transportador, y un metabolito de la misma, donde dicha sustancia original es tamoxifeno y dicho metabolito es endoxifeno. Reivindicación 3: Composición de acuerdo con la reivindicación 2 para pacientes del CYP2D6 IM, caracterizada porque comprende 15 - 25 mg de tamoxifeno y 0,25 - 2,00 mg de endoxifeno.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12170401.9A EP2668945A1 (de) | 2012-06-01 | 2012-06-01 | Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen |
Publications (1)
Publication Number | Publication Date |
---|---|
AR118842A2 true AR118842A2 (es) | 2021-11-03 |
Family
ID=48520964
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130101928 AR091234A1 (es) | 2012-06-01 | 2013-05-31 | Formulaciones farmaceuticas basadas en genotipos o fenotipos, procedimiento para prepararlas |
ARP200101246A AR118842A2 (es) | 2012-06-01 | 2020-04-30 | Composición farmacéutica que contiene tamoxifen y endoxifen y procedimiento para prepararla |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130101928 AR091234A1 (es) | 2012-06-01 | 2013-05-31 | Formulaciones farmaceuticas basadas en genotipos o fenotipos, procedimiento para prepararlas |
Country Status (23)
Country | Link |
---|---|
US (3) | US10285958B2 (es) |
EP (2) | EP2668945A1 (es) |
JP (2) | JP6096289B2 (es) |
KR (1) | KR102129043B1 (es) |
CN (2) | CN110075097A (es) |
AR (2) | AR091234A1 (es) |
AU (1) | AU2013269793B2 (es) |
BR (1) | BR112014030059B1 (es) |
CA (1) | CA2875189C (es) |
DK (1) | DK2854789T3 (es) |
ES (1) | ES2744306T3 (es) |
HK (1) | HK1207296A1 (es) |
HU (1) | HUE045699T2 (es) |
IL (1) | IL235988B (es) |
MX (1) | MX370304B (es) |
NZ (1) | NZ702849A (es) |
PL (1) | PL2854789T3 (es) |
PT (1) | PT2854789T (es) |
RU (1) | RU2683260C2 (es) |
SA (1) | SA113340607B1 (es) |
SG (2) | SG10201610072UA (es) |
TW (1) | TWI644666B (es) |
WO (1) | WO2013178565A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2668945A1 (de) * | 2012-06-01 | 2013-12-04 | Bayer Technology Services GmbH | Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen |
US11965206B2 (en) | 2018-12-21 | 2024-04-23 | John Stoddard | Method of dosing a patient with multiple drugs using adjusted phenotypes of CYP450 enzymes |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1317546C (en) | 1985-07-01 | 1993-05-11 | Werner Meier | Pharmaceutical preparations containing mixtures of hydroxy derivatives of vitamin d |
US6048857A (en) | 1989-10-17 | 2000-04-11 | Ellinwood, Jr.; Everett H. | Dosing method of administering medicaments via inhalation administration |
US5580728A (en) | 1994-06-17 | 1996-12-03 | Perlin; Mark W. | Method and system for genotyping |
US6017963A (en) | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
US6760708B1 (en) | 1999-08-19 | 2004-07-06 | Dell Products L.P. | Method and system for migrating stored data to a build-to-order computing system |
US20020012921A1 (en) | 2000-01-21 | 2002-01-31 | Stanton Vincent P. | Identification of genetic components of drug response |
US7427480B2 (en) | 2002-03-26 | 2008-09-23 | Perlegen Sciences, Inc. | Life sciences business systems and methods |
CN102349927A (zh) * | 2003-08-29 | 2012-02-15 | Hdac默克研究有限责任公司 | 联合治疗癌症的方法 |
US7504214B2 (en) * | 2003-09-19 | 2009-03-17 | Biotheranostics, Inc. | Predicting outcome with tamoxifen in breast cancer |
DE10345836A1 (de) | 2003-10-02 | 2005-04-21 | Bayer Technology Services Gmbh | Verfahren zur Simulation der Wechselwirkung von chemischen Substanzen mit lebenden Organismen |
JP4732683B2 (ja) | 2003-12-29 | 2011-07-27 | ユニバーサル・バイオ・リサーチ株式会社 | 標的物質の検出方法 |
WO2005092314A1 (en) | 2004-03-18 | 2005-10-06 | Istituto Nazionale Per Lo Studio E La Cura Del Tum | 4-oxo-fenretinide, administered alone and in combination with fenretinide, as preventive and therapeutic agent for cancer |
US7805282B2 (en) | 2004-03-30 | 2010-09-28 | New York University | Process, software arrangement and computer-accessible medium for obtaining information associated with a haplotype |
DE102004025534A1 (de) | 2004-05-25 | 2005-12-15 | Bayer Technology Services Gmbh | Verfahren zur (zweistufigen) Dosis- und Dosierungsfindung |
US8024128B2 (en) | 2004-09-07 | 2011-09-20 | Gene Security Network, Inc. | System and method for improving clinical decisions by aggregating, validating and analysing genetic and phenotypic data |
US8147615B2 (en) | 2004-11-05 | 2012-04-03 | Infineon Technologies Ag | Method of fabricating semiconductor cleaners |
JP2008542394A (ja) | 2005-06-02 | 2008-11-27 | バイオベイル・ラボラトリーズ・インターナショナル・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ | 少なくとも1つの形態のベンラファキシンの調節放出性組成物 |
US20070122824A1 (en) | 2005-09-09 | 2007-05-31 | Tucker Mark R | Method and Kit for Assessing a Patient's Genetic Information, Lifestyle and Environment Conditions, and Providing a Tailored Therapeutic Regime |
WO2007035613A1 (en) | 2005-09-19 | 2007-03-29 | Bg Medicine, Inc. | Correlation analysis of biological systems |
RU2318508C2 (ru) * | 2005-12-28 | 2008-03-10 | Всеволод Иванович Киселев | Фармацевтическая композиция для лечения и профилактики пролиферативных заболеваний молочной железы |
FR2896896B1 (fr) | 2006-02-02 | 2009-09-25 | Commissariat Energie Atomique | Procede de classification d'evenements ou d'etats en deux etapes |
DE102006028232A1 (de) | 2006-06-20 | 2007-12-27 | Bayer Technology Services Gmbh | Vorrichtung und Verfahren zur Berechnung und Bereitstellung einer Medikamentendosis |
PT2101731T (pt) | 2006-11-21 | 2018-04-18 | Jina Pharmaceuticals Inc | Endoxifeno para utilização no tratamento de cancro |
US20090291134A1 (en) | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
US8099298B2 (en) | 2007-02-14 | 2012-01-17 | Genelex, Inc | Genetic data analysis and database tools |
WO2009108802A2 (en) | 2008-02-26 | 2009-09-03 | Purdue Research Foundation | Method for patient genotyping |
WO2009120999A2 (en) | 2008-03-28 | 2009-10-01 | Olema Pharmaceuticals, Inc. | Use of an endoxifen prodrug for treatment of breast cancer |
US20100029734A1 (en) * | 2008-05-06 | 2010-02-04 | Ore Pharmaceuticals Inc. | Methods for breast cancer screening and treatment |
KR101950635B1 (ko) | 2008-06-30 | 2019-05-20 | 토카겐 인크. | 5-플루오르시토신 제제 및 이의 용도 |
JP4517312B2 (ja) * | 2008-07-08 | 2010-08-04 | ソニー株式会社 | メモリアクセス制御装置および撮像装置 |
WO2010022143A2 (en) * | 2008-08-19 | 2010-02-25 | Mayo Foundation For Medical Education And Research | Assessing and treating breast cancer patients |
EP2346428B1 (en) | 2008-09-25 | 2019-11-06 | Zeltiq Aesthetics, Inc. | Treatment planning systems and methods for body contouring applications |
US7873482B2 (en) | 2008-12-16 | 2011-01-18 | Bruno Stefanon | Diagnostic system for selecting nutrition and pharmacological products for animals |
WO2010096834A2 (en) | 2009-02-23 | 2010-08-26 | Indiana University Research & Technology Corporation | Materials and methods for treating patients with tamoxifen |
WO2011072244A1 (en) | 2009-12-10 | 2011-06-16 | Mount Sinai School Of Medicine Of New York University | Method of treatment of breast cancer with tamoxifen |
US9372198B2 (en) | 2010-06-17 | 2016-06-21 | Aradigm Corporation | Diagnosis of entry of gastrointestinal contents into respiratory tract of humans and animals |
KR20130101517A (ko) * | 2010-08-26 | 2013-09-13 | 아이피시에이 래버러토리즈 리미티드 | 혈전증 또는 색전증의 치료 또는 예방 방법 |
AU2012277327B2 (en) * | 2011-06-27 | 2017-04-27 | Ipca Laboratories Limited | Anti-thrombotic compounds |
KR20200105524A (ko) | 2012-04-02 | 2020-09-07 | 버그 엘엘씨 | 조사적 세포 기반 분석 및 이의 사용 |
EP2668945A1 (de) | 2012-06-01 | 2013-12-04 | Bayer Technology Services GmbH | Genotyp- bzw. Phänotyp-basierte Arzeimittelformulierungen |
US9417221B2 (en) | 2013-08-27 | 2016-08-16 | International Business Machines Corporation | Food steganography |
-
2012
- 2012-06-01 EP EP12170401.9A patent/EP2668945A1/de not_active Withdrawn
-
2013
- 2013-05-27 ES ES13725157T patent/ES2744306T3/es active Active
- 2013-05-27 WO PCT/EP2013/060824 patent/WO2013178565A1/de active Application Filing
- 2013-05-27 CN CN201910317702.5A patent/CN110075097A/zh active Pending
- 2013-05-27 PL PL13725157T patent/PL2854789T3/pl unknown
- 2013-05-27 PT PT13725157T patent/PT2854789T/pt unknown
- 2013-05-27 BR BR112014030059-3A patent/BR112014030059B1/pt active IP Right Grant
- 2013-05-27 SG SG10201610072UA patent/SG10201610072UA/en unknown
- 2013-05-27 EP EP13725157.5A patent/EP2854789B1/de active Active
- 2013-05-27 AU AU2013269793A patent/AU2013269793B2/en active Active
- 2013-05-27 CA CA2875189A patent/CA2875189C/en active Active
- 2013-05-27 RU RU2014154140A patent/RU2683260C2/ru active
- 2013-05-27 US US14/403,823 patent/US10285958B2/en active Active
- 2013-05-27 HU HUE13725157A patent/HUE045699T2/hu unknown
- 2013-05-27 KR KR1020147036212A patent/KR102129043B1/ko active IP Right Grant
- 2013-05-27 NZ NZ702849A patent/NZ702849A/en unknown
- 2013-05-27 JP JP2015514441A patent/JP6096289B2/ja active Active
- 2013-05-27 DK DK13725157.5T patent/DK2854789T3/da active
- 2013-05-27 MX MX2014014596A patent/MX370304B/es active IP Right Grant
- 2013-05-27 SG SG11201407791VA patent/SG11201407791VA/en unknown
- 2013-05-27 CN CN201380040850.8A patent/CN104507464A/zh active Pending
- 2013-05-31 TW TW102119266A patent/TWI644666B/zh active
- 2013-05-31 AR ARP130101928 patent/AR091234A1/es unknown
- 2013-06-01 SA SA113340607A patent/SA113340607B1/ar unknown
-
2014
- 2014-11-30 IL IL235988A patent/IL235988B/en active IP Right Grant
-
2015
- 2015-08-17 HK HK15107896.3A patent/HK1207296A1/xx unknown
-
2016
- 2016-11-09 JP JP2016219156A patent/JP2017048234A/ja active Pending
-
2017
- 2017-01-31 US US15/420,733 patent/US20170326080A1/en not_active Abandoned
- 2017-06-16 US US15/625,553 patent/US20170326081A1/en not_active Abandoned
-
2020
- 2020-04-30 AR ARP200101246A patent/AR118842A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR11740A (es) | Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada | |
UY31747A (es) | Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparacion | |
UY33370A (es) | Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización | |
CL2010001526A1 (es) | Compuestos derivados de isonicotinamida, moduladores de la estearoil-coa-desaturasa; composicion farmaceutica que comprende un compuesto;utiles para tratar enfermedades relacionadas con dislipidemia y trastornos del metabolismo de lipidos. | |
BR112015014372A8 (pt) | inibidores de autotaxina, seus usos, e composição e combinação farmacêuticas". | |
CU24032B1 (es) | UNA FORMULACIÓN FARMACÉUTICA QUE COMPRENDE 4-[3-(4-CICLOPROPANOCARBONIL-PIPERAZINA-1-CARBONIL)-4-FLUOROBENCIL]-2h-FTALAZIN-1-ONA EN DISPERSIÓN SÓLIDA CON COPOVIDONA | |
CL2012000620A1 (es) | Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20. | |
CL2012000026A1 (es) | Formulación farmacéutica acuosa que contiene una insulina, un análogo de insulina o un derivado insulínico, o una de sus sales farmacológicamente tolerables, y metionina; proceso para preparar dicha formulación; medicamento que la contiene; y su uso para tratar la diabetes mellitus. | |
BR112012032008A2 (pt) | anticorpos s100a4 e usos terapêuticos do mesmo | |
BR112012032282A2 (pt) | administração transdérmica de memantina | |
CY1122868T1 (el) | Φαρμακευτικες συνθεσεις που περιεχουν 2-αμινο-2-[2-(4-οκτυλοφαινυλ)αιθυλ]προπανο-1,3-διολη | |
CO6351689A2 (es) | Formulaciones farmaceuticas que contienen ligandos de receptores de dopamina | |
CR20150266A (es) | Formulaciones de liberación modificada para oprozomib | |
AR082312A1 (es) | Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos | |
BR112014011981A8 (pt) | Formulações farmacêuticas sólidas orais, seus processos de preparação e usos | |
BR112017008993A2 (pt) | métodos e composições especificamente para o tratamento de transtorno de déficit de atenção | |
NI201000189A (es) | Formulación de medicamento sólido con liberación retardadas. | |
BR112014002025A2 (pt) | partículas que compreendem compostos ativos com base em poliacrilato | |
CR20120549A (es) | Composiciones farmacèuticas que comprenden hidromorfona y naloxona | |
BR112012028788A2 (pt) | fabricação de grânulos sem ativos | |
MX344846B (es) | Combinacion de granulos cargados activos con activos adicionales. | |
AR118842A2 (es) | Composición farmacéutica que contiene tamoxifen y endoxifen y procedimiento para prepararla | |
UY32734A (es) | Compuestos agonistas del receptor esfingosina 1-fosfato | |
BR112015030431A2 (pt) | formulação de liberação modificada | |
NI201700066A (es) | Antagonistas de a2a de dosis baja para tratamiento de tdah y la enfermedad de parkinson |